| 4-dedimethylamino tetracycline compounds -> Monitor Keywords |
|
|
 
4-dedimethylamino tetracycline compoundsRelated Patent Categories: Drug, Bio-affecting And Body Treating Compositions, Designated Organic Active Ingredient Containing (doai), Acyclic Nitrogen Double Bonded To Acyclic Nitrogen, Acyclic Nitrogen Triple Bonded To Acyclic Nitrogen Or Azide Doai, 3,10-dihydroxy-2-naphthacene Carboxamide Or Derivative (e.g., Tetracycline, Etc.) Doai4-dedimethylamino tetracycline compounds description/claimsThe Patent Description & Claims data below is from USPTO Patent Application 20060089336, 4-dedimethylamino tetracycline compounds. Brief Patent Description - Full Patent Description - Patent Application Claims
RELATED APPLICATIONS [0001] This application is a continuation of U.S. patent application Ser. No. 10/337,914, filed Jan. 6, 2003; which claims priority to Provisional Patent Application Ser. No. 60/367,049, filed Mar. 21, 2002; U.S. Provisional Patent Application Ser. No. 60/346,930, filed Jan. 8, 2002; U.S. Provisional Patent Application Ser. No. 60/346,929, filed Jan. 8, 2002; U.S. Provisional Patent Application Ser. No. 60/347,065, filed Jan. 8, 2002; and U.S. Provisional Patent Application Ser. No. 60/346,956, filed Jan. 8, 2002. The entire contents of each of these applications are hereby incorporated herein by reference. BACKGROUND OF THE INVENTION [0002] The development of the tetracycline antibiotics was the direct result of a systematic screening of soil specimens collected from many parts of the world for evidence of microorganisms capable of producing bacteriocidal and/or bacteriostatic compositions. The first of these novel compounds was introduced in 1948 under the name chlortetracycline. Two years later, oxytetracycline became available. The elucidation of the chemical structure of these compounds confirmed their similarity and furnished the analytical basis for the production of a third member of this group in 1952, tetracycline. A new family of tetracycline compounds, without the ring-attached methyl group present in earlier tetracyclines, was prepared in 1957 and became publicly available in 1967; and minocycline was in use by 1972. [0003] Recently, research efforts have focused on developing new tetracycline antibiotic compositions effective under varying therapeutic conditions and routes of administration. New tetracycline analogues have also been investigated which may prove to be equal to or more effective than the originally introduced tetracycline compounds. Examples include U.S. Pat. Nos. 2,980,584; 2,990,331; 3,062,717; 3,165,531; 3,454,697; 3,557,280; 3,674,859; 3,957,980; 4,018,889; 4,024,272; and 4,126,680. These patents are representative of the range of pharmaceutically active tetracycline and tetracycline analogue compositions. [0004] Historically, soon after their initial development and introduction, the tetracyclines were found to be highly effective pharmacologically against rickettsiae; a number of gram-positive and gram-negative bacteria; and the agents responsible for lymphogranuloma venereum, inclusion conjunctivitis, and psittacosis. Hence, tetracyclines became known as "broad spectrum" antibiotics. With the subsequent establishment of their in vitro antimicrobial activity, effectiveness in experimental infections, and pharmacological properties, the tetracyclines as a class rapidly became widely used for therapeutic purposes. However, this widespread use of tetracyclines for both major and minor illnesses and diseases led directly to the emergence of resistance to these antibiotics even among highly susceptible bacterial species both commensal and pathogenic (e.g., pneumococci and Salmonella). The rise of tetracycline-resistant organisms has resulted in a general decline in use of tetracyclines and tetracycline analogue compositions as antibiotics of choice. SUMMARY OF THE INVENTION [0005] The invention pertains, at least in part, to 7-substituted 4-dedimethylamino tetracycline compound of Formula I: wherein: [0006] X is CHC(R.sup.13Y'Y) CR.sup.6'R.sup.6, C.dbd.CR.sup.6'R.sup.6, S, NR.sup.6, or O; [0007] R.sup.2 and R.sup.2' are each independently hydrogen, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, arylalkyl, aryl, heterocyclic, heteroaromatic or a prodrug moiety; [0008] R.sup.4 and R.sup.4' are each independently alkyl, alkenyl, alkynyl, hydroxyl, halogen, hydrogen, or when taken together the oxygen of a carbonyl group; [0009] R.sup.2', R.sup.3, R.sup.10, R.sup.11 and R.sup.12 are each hydrogen or a pro-drug moiety; [0010] R.sup.5 is hydroxyl, hydrogen, thiol, alkanoyl, aroyl, alkaroyl, aryl, heteroaromatic, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, arylalkyl, alkyl carbonyloxy, or aryl carbonyloxy; [0011] R.sup.6 and R.sup.6' are each independently hydrogen, methylene, absent, hydroxyl, halogen, thiol, alkyl, alkenyl, alkynyl, aryl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, or an arylalkyl; [0012] R.sup.7 is hydrogen, nitro, alkyl, alkenyl, alkynyl, aryl, heterocyclic, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, arylalkyl, amino, amido, arylalkenyl, arylalkynyl, or --(CH.sub.2).sub.0-3NR.sup.7cC(.dbd.W')WR.sup.7a; [0013] R.sup.9 is hydrogen, nitro, alkyl, alkenyl, alkynyl, aryl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, arylalkyl, amino, amido, arylalkenyl, arylalkynyl, thionitroso(e.g., --N.dbd.S), or --(CH.sub.2).sub.0-3NR.sup.9cC(=Z')ZR.sup.9a; [0014] Z is CR.sup.9dR.sup.9e, S, NR.sup.9b, or O; [0015] Z' is O, S, or NR.sup.9f; [0016] W is CR.sup.7dR.sup.7e, S, NR.sup.7b or O; [0017] W' is O, NR.sup.7fS; [0018] R.sup.7a, R.sup.7b, R.sup.7c, R.sup.7d, R.sup.7e, R.sup.9a, R.sup.9b, R.sup.9c, R.sup.9d, and R.sup.9eare each independently hydrogen, acyl, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, arylalkyl, aryl, heterocyclic, heteroaromatic or a prodrug moiety; [0019] R.sup.8 is hydrogen, hydroxyl, halogen, thiol, alkyl, alkenyl, alkynyl, aryl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, or an arylalkyl; [0020] R.sup.13 is hydrogen, hydroxy, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, or an arylalkyl; and [0021] Y' and Y are each independently hydrogen, halogen, hydroxyl, cyano, sulfhydryl, amino, amido, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, or an arylalkyl, and pharmaceutically acceptable salts thereof. [0022] The invention also pertains to 7-substituted 4-dedimethylamino sancycline compounds of the formula: wherein: Continue reading about 4-dedimethylamino tetracycline compounds... Full patent description for 4-dedimethylamino tetracycline compounds Brief Patent Description - Full Patent Description - Patent Application Claims Click on the above for other options relating to this 4-dedimethylamino tetracycline compounds patent application. ###  How KEYWORD MONITOR works... a FREE service from FreshPatents1. Sign up (takes 30 seconds). 2. Fill in the keywords to be monitored. 3. Each week you receive an email with patent applications related to your keywords. Start now! - Receive info on patent apps like 4-dedimethylamino tetracycline compounds or other areas of interest. ### Previous Patent Application: Compositions and methods for enhancing cognitive function and synaptic plasticity Next Patent Application: Dosage form for hormonal contraception Industry Class: Drug, bio-affecting and body treating compositions ### FreshPatents.com Support Thank you for viewing the 4-dedimethylamino tetracycline compounds patent info. IP-related news and info Results in 0.14991 seconds Other interesting Feshpatents.com categories: Medical: Surgery , Surgery(2) , Surgery(3) , Drug , Drug(2) , Prosthesis , Dentistry 174 |
 * Protect your Inventions * US Patent Office filing 
PATENT INFO |
|
